Evidence map›Paper›PMID 29873771›Full record

ArticleRheumatology (Oxford, England)2018

The SLE-key test serological signature: new insights into the course of lupus.

Chaim Putterman, David S Pisetsky, Michelle Petri, Roberto Caricchio, Alan H B Wu, Ignacio Sanz, Jim C Oates, Steve Wallace, Rachel Sorek, Robert Gerwien and 3 more

Abstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Observational
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chaim PuttermanThe Division of Rheumatology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.
David S PisetskyDurham VA Medical Center, Duke University Medical Center and Medical Research Service, Durham, NC.
Michelle PetriDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD.
Roberto CaricchioTemple Lupus Clinic, Temple University, Philadelphia, PA.
Alan H B WuDepartment of Laboratory Medicine, San Francisco General Hospital, San Francisco, CA.
Ignacio SanzDivision of Rheumatology, Emory University School of Medicine, Atlanta, GA.
Jim C OatesDivision of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC.
Steve WallaceImmunArray Inc., Richmond, VA, USA.
Rachel SorekImmunArray Ltd, Rehovot, Israel.
Robert GerwienGerwien Statistical Consulting, Newington, CT, USA.
Pennina SaferImmunArray Ltd, Rehovot, Israel.
Keren Jakobi-BrookImmunArray Ltd, Rehovot, Israel.
Irun R CohenDepartment of Immunology, The Weizmann Institute of Science, Rehovot, Israel.

Funding

Regulation of B cell Responses in SLE and Other Autoimmune DiseasesU19AI110483 · NIAID · EMORY UNIVERSITY · PI Ignacio E. Sanz · 2014 to 2026
$76.6M
ZINC AND COPPER METABOLISM IN COLLAGEN DISORDERSM01RR001070 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI REVES, JOSEPH G · 1985 to 2009
$16.3M
SOUTH CAROLINA CLINICAL & TRANSLATIONAL RESEARCH INSTITUTE (SCTR)UL1RR029882 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2009 to 2011
$10.1M
Resource CoreP30AR072582 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI JAMES C OATES · 2017 to 2026
$8.5M
Lupus CohortR01AR043727 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 1997 to 2015
$8.2M
Patient Resource CoreP60AR062755 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI SILVER, RICHARD M. · 2012 to 2016
$5.8M
A Model System for the Study of Human B-cell ToleranceR37AI049660 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2010 to 2019
$3.7M
Hopkins Lupus CohortR01AR069572 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 2016 to 2020
$3.4M
Cellular Sources of Self Antigen in SLEI01BX003772 · VA · DURHAM VA MEDICAL CENTER · PI PISETSKY, DAVID STEPHEN · 2018 to 2021
–
BLRD VA I01 BX003772NCRR NIH HHS M01 RR001070NCRR NIH HHS UL1 RR029882NIAID NIH HHS R37 AI049660NIAID NIH HHS U19 AI110483NIAMS NIH HHS P30 AR072582NIAMS NIH HHS P60 AR062755NIAMS NIH HHS R01 AR043727NIAMS NIH HHS R01 AR069572
6 · The paper itself

Abstract

Objective: We previously described the multiplex autoantibody SLE-key Rule-Out test, which detects a signature of autoantibody reactivity that distinguishes healthy subjects from SLE patients with 94% sensitivity, 75% specificity and 93% negative predictive value; thus, an individual manifesting a positive Rule-Out test score is unlikely to have SLE (e.g. lupus is excluded). The objective of this current study was to evaluate the stability of the lupus-associated signature over time. Methods: We used banked serum samples from healthy subjects (n = 51) and lupus patients (n = 50 individual samples and n = 181 paired samples, for a total of n = 412 serum samples). The samples were drawn at different times after diagnosis to analyse the impact on the SLE-key Rule-Out test of time elapsed since diagnosis and any changes in disease activity (as reflected by the SLEDAI score). Results: The SLE signature remains stable for the first 10 years after diagnosis; in this time frame, <10% of patients manifested a positive Rule-Out score and the SLE-key Rule-Out score was independent of the underlying disease activity as reflected by the SLEDAI score. After ⩾10 years, ∼30% of lupus subjects scored as SLE Ruled-Out; the proportion of patients manifesting this status was even greater in the subset of individuals with a SLEDAI score of 0. Conclusion: These findings raise the possibility that a significant number of SLE patients manifest a change in their serological signature over time, and that such a signature change may signify an evolution in the immunological features of their disease relevant to patient management.

Indexed as

ForecastingAdultAutoantibodiesBiomarkersDisease ProgressionFemaleFollow-Up StudiesHumansLupus Erythematosus, SystemicMaleROC CurveSerologic TestsSeverity of Illness IndexAutoantibodiesBiomarkers

Identifiers

PMID29873771
PMCPMC6105919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.